







an Open Access Journal by MDPI

Adhesion and Integrins

Guest Editor:

Prof. Kairbaan Hodivala-Dilke

Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, Charterhouse Square, London ECIM 6BQ, UK

Deadline for manuscript submissions:

closed (30 October 2012)

Message from the Guest Editor

Dear Colleagues,

Cancer initiation, growth, progression and metastasis are all stages of the disease that involve changes in both cell-cell and cell-matrix adhesion. Such changes occur not only the tumour cell compartment but also in the stromal compartment, with changes in the adhesive capacity of immune cells, tumour associated fibroblasts, endothelial cells and so on. It is increasing evident that blockade of such adhesion molecules may have therapeutic value. The special issue of Cancers on 'Adhesion and Integrins' will include original research articles and review articles on the influence of adhesion molecules in cancer development and how we can exploit such changes for therapeutic advance.

Prof. Kairbaan Hodivala-Dilke *Guest Editor*













an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us